2.22
+0.11(+5.21%)
Currency In USD
Address
427 Park Street
Newton, VA 22902
United States of America
Phone
434 297 1000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
61
First IPO Date
July 01, 2021
| Name | Title | Pay | Year Born |
| Mr. Daniel J. O'Connell M.B.A. | Chief Executive Officer & Director | 1.05M | 1970 |
| Dr. Grant A. Krafft Ph.D. | Co-Founder | 42,000 | N/A |
| Mr. Russell Barton M.S. | Chief Operating Officer | 223,680 | 1959 |
| Mr. Matt Zuga | Chief Financial Officer & Chief Business Officer | 703,157 | N/A |
| Dr. James Doherty Ph.D. | President & Chief Development Officer | 730,785 | 1968 |
| Mr. Derek M. Meisner Esq., J.D. | Chief Legal Officer & Corporate Secretary | 752,945 | 1971 |
| Ms. Alex Braun M.B.A. | Vice President & Head of Investor Relations | 0 | N/A |
| Ms. Kelly Carranza | Vice President, Finance & Accounting and Corporate Controller | 0 | N/A |
| Dr. Caleb E. Finch Ph.D. | Co-Founder | 0 | N/A |
| Dr. William L. Klein Ph.D. | Co-Founder | 0 | N/A |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.